Journal
ONCOGENE
Volume 33, Issue 41, Pages 4932-4940Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2013.435
Keywords
NKG2D receptor; breast cancer; xenotransplant; angiogenesis; metastasis
Funding
- Erwin Schrodinger Fellowship from the Austrian Science Fund (FWF) [J3078]
- NIH/NCI Pacific Ovarian Cancer Research Consortium (POCRC) SPORE [P50 CA083636]
- NIH/NCI [R01 CA174470]
- Austrian Science Fund (FWF) [J3078] Funding Source: Austrian Science Fund (FWF)
Ask authors/readers for more resources
The stimulatory NKG2D lymphocyte receptor together with its tumor-associated ligands enable the immune system to recognize and destroy cancer cells. However, with dynamic changes unfolding, cancers exploit NKG2D and its ligands for immune evasion and suppression. Recent findings have added yet another functional dimension, wherein cancer cells themselves co-opt NKG2D for their own benefit to complement the presence of its ligands for self-stimulation of parameters of tumorigenesis. Those findings are here extended to in vivo tumorigenicity testing by employing orthotopic xenotransplant breast cancer models in mice. Using human cancer lines with ectopic NKG2D expression and RNA interference (RNAi)-mediated protein depletion among other controls, we show that NKG2D self-stimulation has tumor-promoting capacity. NKG2D signals had no notable effects on cancer cell proliferation and survival but acted at the level of angiogenesis, thus promoting tumor growth, tumor cell intravasation and dissemination. NKG2D-mediated effects on tumor initiation may represent another factor in the observed overall enhancement of tumor development. Altogether, these results may have an impact on immunotherapy approaches, which currently do not account for such NKG2D effects in cancer patients and thus could be misdirected as underlying assumptions are incomplete.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available